CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Phase 2

Completed

Conditions: Hemophilia A

Interventions: Biological: rVIII-SingleChain
Biological: Octocog alfa

First Posted Date: 2011-12-07

Last Posted Date: 2016-08-09

Lead Sponsor: CSL Behring

Target Recruit Count: 175

Registration Number: NCT01486927

Locations: 🇬🇧
Study Site, London, United Kingdom

Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery

Phase 3

Completed

Conditions: Surgical Blood Loss
Postoperative Blood Loss

Interventions: Biological: Fibrinogen Concentrate (Human) (FCH)
Biological: Placebo

First Posted Date: 2011-11-21

Last Posted Date: 2014-09-18

Lead Sponsor: CSL Behring

Target Recruit Count: 152

Registration Number: NCT01475669

Locations: 🇧🇷
InCor, Sao Paulo, Brazil
🇩🇰
Kobenhavns Universitet-Det Sundhedsvidenskabelige Fakultet, Copenhagen, Denmark
🇮🇹
Azienda Ospedaliera di Udine, Udine, Italy

and more 32 locations

Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

Phase 4

Completed

Conditions: Hereditary Angioedema Types I and II

Interventions: Biological: Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection

First Posted Date: 2011-11-09

Last Posted Date: 2017-02-06

Lead Sponsor: CSL Behring

Target Recruit Count: 46

Registration Number: NCT01467947

Locations: 🇷🇴
Spitalul Clinic Judeţean Mureş,Secţia Clinică Medicină Internă,Compartimentul Alergologie şi Imunologie, Târgu-Mures, Mureş, Romania
🇧🇬
MHAT "Tsaritsa Yoanna", Sofia, Bulgaria
🇵🇱
Jagiellonian University, Krakow, Poland

and more 1 locations

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Phase 3

Completed

Conditions: Primary Immune Deficiency

Interventions: Biological: Immune globulin subcutaneous (Human)

First Posted Date: 2011-10-27

Last Posted Date: 2014-12-02

Lead Sponsor: CSL Behring

Target Recruit Count: 22

Registration Number: NCT01461018

Locations: 🇯🇵
Study site, Bunkyo-ku, Tokyo Metropolitan, Japan
🇯🇵
Study Site, Sapporo city, Hokkaido, Japan

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Phase 3

Completed

Conditions: Primary Immune Deficiency Disorder

Interventions: Biological: Immune globulin subcutaneous (Human)

First Posted Date: 2011-10-24

Last Posted Date: 2013-04-09

Lead Sponsor: CSL Behring

Target Recruit Count: 23

Registration Number: NCT01458171

Locations: 🇯🇵
Study site, Bunkyo-ku, Tokyo Metropolitan, Japan

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development

Phase 3

Terminated

Conditions: Hemophilia A

Interventions: Biological: Biostate

First Posted Date: 2011-10-03

Last Posted Date: 2017-10-03

Lead Sponsor: CSL Behring

Target Recruit Count: 1

Registration Number: NCT01445197

Locations: 🇷🇺
Study Site, Barnaul, Russian Federation

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Phase 2

Terminated

Conditions: Oral Mucositis

Interventions: Biological: ALD518
Drug: 0.9% saline

First Posted Date: 2011-07-27

Last Posted Date: 2021-05-11

Lead Sponsor: CSL Behring

Target Recruit Count: 76

Registration Number: NCT01403064

Locations: 🇺🇸
Morton Plant Mease Health Care, Clearwater, Florida, United States
🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States

and more 28 locations

A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)

Phase 4

Completed

Conditions: Immune Thrombocytopenic Purpura

Interventions: Biological: IgPro10

First Posted Date: 2011-07-11

Last Posted Date: 2016-04-08

Lead Sponsor: CSL Behring

Target Recruit Count: 57

Registration Number: NCT01390649

Locations: 🇧🇬
UMHAT "Dr. Georgi Stranski" Clinic of Haematology, Pleven, Bulgaria
🇷🇴
Emergency Clinical County Hospital Baia Mare, Baia Mare, Romania
🇷🇴
Emergency Clinical County Hospital Brasov, Brasov, Romania

and more 14 locations

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: BMS-945429
Drug: BMS-945429 Placebo
Drug: Adalimumab
Drug: Methotrexate Placebo
Drug: Methotrexate
Drug: Adalimumab Placebo

First Posted Date: 2011-06-14

Last Posted Date: 2021-12-06

Lead Sponsor: CSL Behring

Target Recruit Count: 418

Registration Number: NCT01373151

Locations: 🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸
Arthritis Associates Of Mississippi, Jackson, Mississippi, United States
🇺🇸
Box Arthritis And Rheumatology Of The Carolinas, Pllc, Charlotte, North Carolina, United States

and more 12 locations

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

Phase 1

Completed

Conditions: Hemophilia B

Interventions: Biological: Recombinant Coagulation Factor IX Albumin Fusion Protein

First Posted Date: 2011-05-26

Last Posted Date: 2016-05-09

Lead Sponsor: CSL Behring

Target Recruit Count: 17

Registration Number: NCT01361126

Locations: 🇮🇱
Study Site, Tel Aviv, Israel

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy